Patents by Inventor Alan David Swinamer

Alan David Swinamer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8299123
    Abstract: The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: October 30, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kaka Dey, Donghong Amy Gao, Daniel R. Goldberg, Alexander Heim-Riether, John Edward Mangette, Ingo Andreas Mugge, Roger John Snow, Alan David Swinamer, Jiang-Ping Wu, Zhaoming Xiong, Yu Yang
  • Patent number: 8263597
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: September 11, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Daniel Kuzmich, Can Mao, Alan David Swinamer, David Smith Thomson
  • Publication number: 20120136158
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Application
    Filed: February 8, 2012
    Publication date: May 31, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
  • Publication number: 20120035370
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
  • Publication number: 20110294808
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 18, 2011
    Publication date: December 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Daniel KUZMICH, Can MAO, Alan David SWINAMER, David Smith THOMSON
  • Patent number: 8063065
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Darren Di Salvo, Christian Harcken, Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, Can Mao, Jochen Neu, Brian Christopher Raudenbush, Hossein Razavi, Alan David Swinamer
  • Publication number: 20110230521
    Abstract: Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: May 1, 2009
    Publication date: September 22, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas Cook, Christian Harcken, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, CAN Mao, Wang Mao, Brain Christopher Raudenbush, Hossein Razavi, Christopher Ronald Sarko, Alan David Swinamer
  • Patent number: 8008327
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: August 30, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darren DiSalvo, Daniel Kuzmich, Can Mao, Hossein Razavi, Christopher Ronald Sarko, Alan David Swinamer, David Smith Thomson, Qiang Zhang
  • Publication number: 20110118262
    Abstract: Disclosed are compounds of formula (I) and compositions of the present invention which are inhibitors of the sodium proton exchanger isoform-1 (NHE-I). Also disclosed are methods of using and making the same.
    Type: Application
    Filed: June 24, 2009
    Publication date: May 19, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joerg Martin Bentzien, Stephen James Boyer, Jennifer Burke, Anne Bettina Eldrup, Xin Guo, John David Huber, Thomas Martin Kirrane, Fariba Soleymanzadeh, Alan David Swinamer
  • Publication number: 20110086846
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Application
    Filed: December 16, 2010
    Publication date: April 14, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas COOK, Darren DiSALVO, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Alan David SWINAMER
  • Publication number: 20110039851
    Abstract: The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.
    Type: Application
    Filed: October 14, 2008
    Publication date: February 17, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Kaka Dey, Donghong Amy Gao, Daniel R. Goldberg, Alexander Heim-Riether, John Edward Mangette, Ingo Andreas Mugge, Roger John Snow, Alan David Swinamer, Jiang-Ping Wu, Zhaoming Xiong, Yu Yang
  • Publication number: 20110034512
    Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: April 23, 2009
    Publication date: February 10, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Darren Disalvo, Daniel Kuzmich, Can Mao, Hossein Razavi, Christopher Sarko, Alan David Swinamer, David Smith Thomson, Qiang Zhang
  • Patent number: 7879873
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: February 1, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Darren DiSalvo, Daniel Robert Fandrick, Christian Harcken, Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, Can Mao, Jochen Neu, Brian Christopher Raudenbush, Hossein Razavi, Jonathan Timothy Reeves, Jinhua J. Song, Alan David Swinamer, Zhulin Tan
  • Publication number: 20100093724
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Application
    Filed: September 22, 2009
    Publication date: April 15, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
  • Patent number: 7569568
    Abstract: Disclosed are compounds of formula (I) Where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: August 4, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek A. Cogan, Ming-Hong Hao, Kevin Chungeng Qian, Alan David Swinamer
  • Patent number: 7550461
    Abstract: Disclosed are amide compounds of formula (I): wherein Ar1, Q, Y and R3-R6 of formula (I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: June 23, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Donghong Amy Gao, Daniel R. Goldberg, Abdelhakim Hammach, Ming-Hong Hao, Victor Marc Kamhi, Neil Moss, Kevin Chungeng Qian, Gregory Paul Roth, Christopher Ronald Sarko, Alan David Swinamer, Zhaoming Xiong
  • Publication number: 20090111791
    Abstract: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.
    Type: Application
    Filed: March 8, 2007
    Publication date: April 30, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephane De Lombaert, Anne Bettina Eldrup, Jennifer A. Kowalski, Ingo Andreas Mugge, Fariba Soleymanzadeh, Alan David Swinamer, Steven John Taylor
  • Publication number: 20090099184
    Abstract: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.
    Type: Application
    Filed: February 15, 2007
    Publication date: April 16, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephane Delombaert, Anne Bettina Eldrup, Neil Alexander Farrow, Jennifer A. Kowalski, Ingo Andreas Mugge, Fariba Soleymanzadeh, Alan David Swinamer, Steve John Taylor
  • Patent number: 7514458
    Abstract: Disclosed compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: April 7, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek Cogan, Ming-Hong Hao, Victor Marc Kamhi, Craig Andrew Miller, Matthew Russell Netherton, Alan David Swinamer
  • Patent number: 7485657
    Abstract: Disclosed are compounds of formula (I) The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and the pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: February 3, 2009
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Derek Cogan, Ming-Hong Hao, Alan David Swinamer, Ronald A. Aungst